用英文对下面的摘要进行专业评价并提出问题：AbstractAims Radiofrequency ablation RFA is clinically adopted to destroy hepatocellular carcinoma but is often incapable of completely ablating large tumors and those with multip

This abstract discusses the development of a magnetic vascular embolic agent for use in combinational treatment of hepatocellular carcinoma. The agent is designed to embolize tumor vessels, enhance the efficacy of radiofrequency ablation (RFA), and inhibit lactic acid production, which can inhibit immune responses. The study found that the combinational therapy significantly inhibited lactic acid production and reversed its accumulation-related immunosuppressive microenvironment. Additionally, the combination of the agent with anti-programmed cell death protein-1 antibody (aPD-1) immune checkpoint blockade induced a robust antitumor response against both primary tumors and distant tumors.

Overall, this abstract presents a comprehensive study on the use of a magnetic vascular embolic agent in combinational therapy for hepatocellular carcinoma. The study's findings suggest that the agent can effectively embolize tumor vessels, enhance the efficacy of RFA, and inhibit lactic acid production, thereby improving immune responses. However, the abstract does not provide information on the sample size or the methods used to assess the efficacy of the combinational therapy. Additionally, the abstract does not discuss the potential limitations or future directions of this study